Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Eribulin + POL6326 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Eribulin | Halaven | Antimicrotubule Agent 14 | ||
POL6326 | Balixafortide | CXCR4 Inhibitor 15 | Balixafortide (POL6326) binds to CXCR4 and inhibits SDF-1 (CXCL12) binding, potentially resulting in increased mobilization of hematopoietic cells (PMID: 29706375). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03786094 | Phase III | Eribulin Eribulin + POL6326 | Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer | Terminated | USA | ITA | GBR | FRA | ESP | CZE | BRA | BEL | ARG | 4 |